Table 1.

CI values of SU6668 with paclitaxel on endothelial and smooth muscle cells

Cell lineDrugsCI
IC30IC50IC70
HUVECSU6668 + PTX0.35 ± 0.090.45 ± 0.090.57 ± 0.06
HMVECSU6668 + PTX0.25 ± 0.140.39 ± 0.230.34 ± 0.10
AoSMCSU6668 + PTX0.40 ± 0.020.47 ± 0.110.58 ± 0.11
  • NOTE: The CI was evaluated for the combination of SU6668 with paclitaxel at IC30, IC50, and IC70 of each drug for HUVEC/HMVEC/AoSMC after 72-hour exposure (experiment as in Fig. 1). The CI was calculated as described in Materials and Methods and evaluated such that CI < 1 is synergism, CI > 1 is antagonism, and CI = 1 is additivity. Data are expressed as mean ± SE of all available pairs of concentrations producing the indicated growth inhibition and are representative of one experiment, repeated at least thrice.

    Abbreviation: PTX, paclitaxel.